A large study has found that women in remission for ovarian cancer who started chemotherapy to prevent a recurrence based on blood levels of the protein CA125 did not live longer than women who started chemotherapy only after symptoms of the disease arose.
The findings, several gynecologic cancer experts said, should influence clinical practice and make clinicians rethink how they monitor patients for recurrence and initiate additional treatments, or salvage therapies. Read more > >
-
Study finds that use of computed tomography led to high rates of follow-up testing
-
Gemcitabine plus cisplatin may be new standard of care for advanced disease
-
Adding trastuzumab to chemotherapy modestly improved overall survival
-
Determining HPV status helps predict treatment response and may become routine
-
The angiogenesis inhibitor delayed but did not prevent recurrence in a phase III trial
-
Results from two phase II trials of PARP inhibitors show promise
-
Using radio waves to heat and destroy abnormal cells may be an alternative to surgery
-
Researchers measured chemical levels in the home and examined risk of ALL
The NCI Cancer Bulletin is produced by the National Cancer Institute (NCI), which was established in 1937. Through basic, clinical, and population-based biomedical research and training, NCI conducts and supports research that will lead to a future in which we can identify the environmental and genetic causes of cancer, prevent cancer before it starts, identify cancers that do develop at the earliest stage, eliminate cancers through innovative treatment interventions, and biologically control those cancers that we cannot eliminate so they become manageable, chronic diseases.
For more information about cancer, call 1-800-4-CANCER or visit http://www.cancer.gov.
NCI Cancer Bulletin staff can be reached at ncicancerbulletin@mail.nih.gov.
